Trait: response to beta blocker

Experimental Factor Ontology (EFO) Information
Identifier EFO_0007766
Description Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a beta blocker stimulus
Trait category
Biological process

Associated Polygenic Score(s)

Filter PGS by Participant Ancestry
Individuals included in:
G - Source of Variant Associations (GWAS)
D - Score Development/Training
E - PGS Evaluation
List of ancestries includes:
Display options:
Ancestry legend
Multi-ancestry (including European)
Multi-ancestry (excluding European)
African
East Asian
South Asian
Additional Asian Ancestries
European
Greater Middle Eastern
Hispanic or Latin American
Additional Diverse Ancestries
Not Reported
Polygenic Score ID & Name PGS Publication ID (PGP) Reported Trait Mapped Trait(s) (Ontology) Number of Variants Ancestry distribution
GWAS
Dev
Eval
 Scoring File (FTP Link)
PGS000718
(PRPBB_44)
 PGP000134 |
Lanfear DE et al. Circ Heart Fail (2020)
 Beta-blocker survival benefit response to beta blocker 44
-
 https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000718/ScoringFiles/PGS000718.txt.gz

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM) 		Evaluated Score PGS Sample Set ID
(PSS) 		Performance Source Trait PGS Effect Sizes
(per SD change) 		Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM001643 PGS000718
(PRPBB_44)
 PSS000852|
European Ancestry|
1,188 individuals
 PGP000134 |
Lanfear DE et al. Circ Heart Fail (2020)
 Reported Trait: Response to beta blocker (reduction in cardiovascular death) in heart failure patients — — P-value (treatment benefit in low vs. high PRP patients): 0.046 Meta-Analysis Global Group in Chronic Heart Failure Score, beta-blocker propensity score Low polygenic response predictor score < 30th percentile of derviation group
PPM001642 PGS000718
(PRPBB_44)
 PSS000851|
European Ancestry|
1,188 individuals
 PGP000134 |
Lanfear DE et al. Circ Heart Fail (2020)
 Reported Trait: Response to beta blocker (reduction in all-cause mortality) in heart failure patients — — P-value (treatment benefit in low vs. high PRP patients): 0.024 Meta-Analysis Global Group in Chronic Heart Failure Score, beta-blocker propensity score Low polygenic response predictor score < 30th percentile of derviation group
PPM018550 PGS000718
(PRPBB_44)
 PSS011019|
European Ancestry|
7,141 individuals
 PGP000481 |
Lanfear DE et al. Circ Genom Precis Med (2023)
|Ext.		 Reported Trait: Survival — — beta (PRPcategory*BB-exposure): 0.576 — —

Evaluated Samples

PGS Sample Set ID
(PSS) 		Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS011019 — — 7,141 individuals,
66.0 % Male samples
 — European — UKB —
PSS000851 Cases = number of cardiovascular deathsHFPGR: Patients with left ventricular ejection fraction (LVEF) <50% were included. Beta-blocker (BB) exposure was calculated from pharmacy claims (ie, drug actually dispensed to patient) and was updated over time. Beta-blocker (BB) exposure was calculated from pharmacy claims (ie, drug actually dispensed to patient) and was updated over time. TIME-CHF: Patients with analysable data and a baseline LVEF <50% were included. BB exposure was calculated from the specific drug and dose at baseline, using the same dose-equivalence scheme as HFPGR but implemented without any updates over time and without information on medication dispensing (ie, assumes patients were receiving the dose prescribed). HF-ACTION: BB exposure was calculated from the specific drug and dose at baseline, using the same dose-equivalence scheme as HFPGR but implemented without any updates over time and without information on medication dispensing (ie, assumes patients were receiving the dose prescribed). —
[
  • 200 cases
  • , 988 controls
]
 — European — HF-ACTION, HFPGR, TIME-CHF —
PSS000852 Cases = number of all cause deaths. HFPGR: Patients with left ventricular ejection fraction (LVEF) <50% were included. Beta-blocker (BB) exposure was calculated from pharmacy claims (ie, drug actually dispensed to patient) and was updated over time. Beta-blocker (BB) exposure was calculated from pharmacy claims (ie, drug actually dispensed to patient) and was updated over time. TIME-CHF: Patients with analysable data and a baseline LVEF <50% were included. BB exposure was calculated from the specific drug and dose at baseline, using the same dose-equivalence scheme as HFPGR but implemented without any updates over time and without information on medication dispensing (ie, assumes patients were receiving the dose prescribed). HF-ACTION: BB exposure was calculated from the specific drug and dose at baseline, using the same dose-equivalence scheme as HFPGR but implemented without any updates over time and without information on medication dispensing (ie, assumes patients were receiving the dose prescribed). —
[
  • 279 cases
  • , 909 controls
]
 — European — HF-ACTION, HFPGR, TIME-CHF —